Claris Lifesciences, an Ahmedabad based global pharmaceutical company specialized in manufacturing and marketing sterile injectable products, has entered into a partnership with Pfizer Inc., the world's largest pharmaceutical company, to commercialize sterile injectable drugs that are off-patent, and have lost market exclusivity in the United States, Canada, Australia, New Zealand and Europe.

Pfizer gets access to versatile sterile injectables portfolio of products backed by strong development, manufacturing and regulatory capabilities of Claris, who has been a strong global injectables player.

Under the terms of this relationship, Pfizer has access to a large basket of injectable products in the United States, Canada, Australia, New Zealand and Europe. These drugs cover a broad range of therapeutic areas including anti-infectives and other critical care products. This partnership is part of Pfizer's Established Products Strategy of providing high quality, affordable medicines to patients and consumers resulting into greater access to health care.

Kelvin Cooper, senior V P - portfolio development, Established Products Business Unit, Pfizer Inc - Worldwide Pharmaceutical Operations, said, "These agreements advance our goals to expand our sterile portfolio and provide patients with a wide offering of high quality affordable medicines they can trust. Pfizer's reputation of high quality and reliable supply is unrivaled in the industry."

"These agreements with Claris represent solid, measurable progress of our strategy to transform Pfizer's Established Products portfolio into an engine of growth. We are excited about this relationship with Claris who is a high quality developer and manufacturer of complex injectable products," Cooper added.

Commenting on the development, Arjun Handa, managing director and CEO, Claris Lifesciences said, "In the era of alliances and partnerships and with the big shifts happening in the global pharmaceutical industry, this relationship will keep Claris at the forefront of this change. Claris will get access to extremely competent sales and marketing partner for its regulated markets strategy, thus enhancing its existing presence in these markets. This relationship speaks of volumes of our manufacturing, quality and global reach. We have been a focused company in sterile injectables and this relationship with Pfizer Established Products will help us to continue our focus in the segment, while expanding our product lines and market access."